HGEN - Kamada: Under-The-Radar COVID-19 Therapy Play With Downside Protection And Margin Of Safety

Disclaimer: This report is the work of an investment adviser affiliated with the author. The report is the result of the adviser executing its investment strategy. The adviser holds a position in the security, however there is no assurance that the adviser will continue to hold the investment, or make additional investments and will not update the information to reflect future changes in the adviser’s assessment of the investment.

Kamada ([[KMDA]] US) Executive Summary:

• US and global pharma companies that are working on credible COVID-19 treatments are up massively YTD, often more than 100% and